Stevanato Group SpA (STVN)
20.66
-0.63
(-2.96%)
USD |
NYSE |
Dec 10, 14:50
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 5.640B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | 3.82% |
| Valuation | |
| PE Ratio | 36.32 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 4.355 |
| Price to Book Value | 3.340 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | 0.0610 |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.3133 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | -- |
Profile
| Stevanato Group SpA engages in the provision of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It operates through the following segments: Biopharmaceutical and Diagnostic Solutions, and Engineering segments. The Biopharmaceutical and Diagnostic Solutions segment includes all the products, processes, and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables. The Engineering segment deals with all the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology and diagnostic manufacturing processes. The company was founded by Giovanni Stevanato in 1949 and is headquartered in Piombino Dese, Italy. |
| URL | http://www.stevanatogroup.com |
| Investor Relations URL | https://ir.stevanatogroup.com/ |
| HQ State/Province | Padova |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Next Earnings Release | Mar. 05, 2026 (est.) |
| Last Earnings Release | Nov. 06, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Jun. 05, 2025 |
Ratings
Profile
| Stevanato Group SpA engages in the provision of drug containment, drug delivery, and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It operates through the following segments: Biopharmaceutical and Diagnostic Solutions, and Engineering segments. The Biopharmaceutical and Diagnostic Solutions segment includes all the products, processes, and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables. The Engineering segment deals with all the equipment and technologies developed and provided to support the end-to-end pharmaceutical, biotechnology and diagnostic manufacturing processes. The company was founded by Giovanni Stevanato in 1949 and is headquartered in Piombino Dese, Italy. |
| URL | http://www.stevanatogroup.com |
| Investor Relations URL | https://ir.stevanatogroup.com/ |
| HQ State/Province | Padova |
| Sector | Health Care |
| Industry | Life Sciences Tools & Services |
| Next Earnings Release | Mar. 05, 2026 (est.) |
| Last Earnings Release | Nov. 06, 2025 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | Jun. 05, 2025 |